11 min listen
AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
12 minutes
Released:
Jan 17, 2023
Format:
Podcast episode
Description
Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes remains the biggest cause of chronic kidney disease, over half of patients with chronic kidney disease do not have diabetes, so treatments that work in people with and without diabetes are key. In this interview, David Preiss MBChB, MRCP, FRCPath, PhD and Cindy L. Grines MD, FACC, MSCAI discuss AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with CKD. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Released:
Jan 17, 2023
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: Strategies to Maximize Doses and Introduce New Medication: As HF therapy continues to evolve, barriers like medication cost and non-adherence may impede patient care. Pharmacists can overcome these barriers through collaborative practice agreements and patient and provider education. In this interview, Sean... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research